Erlotinib With or Without Hydroxychloroquine in Chemo-Naive Advanced NSCLC and (EGFR) Mutations

PHASE2Active, not recruitingINTERVENTIONAL
Enrollment

76

Participants

Timeline

Start Date

October 31, 2009

Primary Completion Date

May 31, 2015

Study Completion Date

December 31, 2027

Conditions
Non-small Cell Lung Cancer
Interventions
DRUG

Erlotinib

150 mg taken orally once daily

DRUG

Hydroxychloroquine

1000 mg taken orally once daily after erlotinib

Trial Locations (4)

21201

University of Maryland, Baltimore

94305

Stanford Cancer Institute, Stanford

06519

Yale Cancer Center, New Haven

02114

Massachusetts General Hospital, Boston

Sponsors

Collaborators (1)

All Listed Sponsors
collaborator

Stanford University

OTHER

collaborator

Yale University

OTHER

collaborator

University of Maryland

OTHER

collaborator

Genentech, Inc.

INDUSTRY

lead

Massachusetts General Hospital

OTHER